Stoke Therapeutics, Inc. (STOK)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $26.41
- As of
Kresmion compiles this page from STOK's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Stoke Therapeutics, Inc. (STOK): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-03.
See the full STOK dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for STOK on one page. Preview it with sample data, then open it live with a free account.
Preview the STOK dossierActive events for STOK
- mediumEarnings below estimates
Q3-2026: Missed consensus by 14.0%, EPS $-1.08 vs $-0.9471 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +5105% to STOK (2026Q2)
- medium13F: new position
TWO SIGMA INVESTMENTS, LP new position in STOK
- mediumEarnings below estimates
Q2-2026: Missed consensus by 14.6%, EPS $-0.93 vs $-0.8112 estimate
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +673% to STOK (2026Q1)
FREE, NO ACCOUNT
Every event on STOK, as it fires
You are seeing 5 of 9 events recorded on STOK since 2026-05-24.
The five above landed across 4 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, STOK
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on STOK
STOK against its peers
STOK's operating margin of -11.2% ranks in the 77th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-03-31.
| Metric | STOK | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 184M USD | 76.3M USD | 63 | 14 |
| Gross margin | n/a | 88.5% | n/a | 7 |
| Operating margin | -11.2% | -117.0% | 77 | 14 |
| Net margin | -3.7% | -106.4% | 78 | 15 |
| Return on equity | -2.0% | -43.5% | 85 | 16 |
| 1 year | -4.7% | 1.9% | 39 | 18 |
Peers (19): NRIX, ZBIO, AGIO, MESO, RARE, VIR, MAZE, BCRX, NBTX, SRPT, VCYT, SEPN, FBRX.D, PGEN, QURE, REPL, SLS, AUPH, RAPP. Left out: KLRA (no annual filing), GENB (no annual filing), COAG (no annual filing), BRVE (no annual filing), TRAX (no annual filing), LYCA (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (STOK: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in STOK on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on STOK in the last 180 days.
Upstream: SEC EDGAR filings for STOK
Kresmion, "Stoke Therapeutics, Inc. (STOK) institutional holdings and SEC filings", data as of 2026-11-03, https://kresmion.com/research/STOK. Upstream data: SEC EDGAR filings for STOK.
Link to this data (HTML):
<a href="https://kresmion.com/research/STOK">Stoke Therapeutics, Inc. (STOK) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow STOK on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to STOK for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.